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Risk factors for the preservation of morphological 
changes in the gastric mucosa after eradication therapy 
for Helicobacter pylori infection in children with chronic 
gastritis
Margarita M. Gurova1,2*, Tatyana А. Romanova1, Valeria P. Novikova2, Valentina S. Popova1
INTRODUCTION
Pathology of the digestive system is one of the main 
causes of the deterioration of health in children 
and adolescents. Along with the steady increase in 
the incidence of chronic gastroduodenitis (CGD), 
exacerbation of the course of the pathological process 
is noted - the proportion of erosive, subatrophic, and 
atrophic forms increases by 2.5 times,[1] Lazarev and 
Gordeeva.[2] The above changes are due to the high 
incidence of helicobacteriosis (HP) in childhood, 
reaching, according to data of various authors, 
50–80%,[3] Baingana et al.[4] and Lee et al.,[5] and the 
increased resistance of HP to the therapy,[6] Ivashkin 
et al.[7], Megraud et al.[8], and Dekhnich et al.[9] Given that 
in 60–80% of adult patients with CGD, the formation 
of the inflammatory process begins in childhood, 
the progression of the disease with subsequent 
atrophy increases the risk of dysplasia and metaplasia 
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underlying carcinogenesis,[10] Koshimbetova.[11] One 
of the unresolved and insufficiently studied questions 
remains the management of patients with CGD 
in remission after successful HP eradication. The 
continuing changes in the regulatory systems of the 
body, underlying impairments of the motor function of 
the upper gastrointestinal tract (GIT), immune system, 
and changes in the intestinal microbiota can contribute 
not only to the recurrence of the disease but also to the 
development of comorbid conditions and metabolic 
disorders.[12]
The relevance of this study is determined by the 
need to study the clinical and morphofunctional 
characteristics of the state of the upper digestive tract 
in children with CGD in remission after eradication of 
Helicobacter pylori (HP) infection.
Objective
The objective of this study was to identify the 
risk factors for the development of persistent 
morphological changes in the gastric mucosa (GM) 
on the basis of studying the characteristics of the 
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morphofunctional state of the upper GIT, the state 
of the intestinal microbiota, and the immune system 
in the acute phase, 3 and 6 months after eradication 
therapy.
MATERIALS AND METHODS
The study included 155 children aged 12–16 years 
(mean age 14.9 ± 2.1 years) with CGD associated with 
HP (38% of children were infected with toxigenic 
strains containing the CagA+ pathogenicity islet) 
being observed in the phase of exacerbation and 
remission (100 children): 3 and 6 months after a 
successful eradication. The control group consisted of 
30 children of health Group 1.
Inclusion Criteria for the Main Group
1. Morphologically confirmed diagnosis of CGD 
associated with HP
2. Voluntary informed consent of the parents (and/
or their legal representatives) of patients for 
inclusion in the study, the invasive examinations and 
processing the data obtained during the subsequent 
observation of the child 3 and 6 months after the 
conducted treatment (in accordance with the ethical 
standards of the Helsinki Declaration [2000] and the 
Order of the MH RF No. 266 of June 19, 2003).
Exclusion Criteria
The following criteria were excluded from the study:
1. Gastric and/or duodenal ulcer, the presence of other 
serious organic diseases of the GIT
2. Severe concomitant somatic diseases
3. Acute infectious diseases at the time of the study
4. Celiac disease and/or other diseases manifested by 
malabsorption syndrome (based on the negative 
results of the determination of AB immunoglobulins 
A (IgA) to transglutaminase)
5. Activation of latent viruses (cytomegalovirus, 
Epstein–Barr virus, type 1 and 2 herpes viruses).
In the acute phase of CGD, children underwent three-
component eradication therapy for 10 days, which 
included a proton-pump inhibitor (Omeprazole), 
amoxicillin (Flemoxin Solutab), clarithromycin 
(Klacid), and a probiotic (live acidophilic lactobacilli 
107 CFU and kefir fungal polysaccharide 400 µg) in 
standard age-specific does.
In the remission phase (after 6 months), depending 
on the morphological features of the GM, the 
children (n = 100) were divided into two subgroups: 
Subgroup 1 (n = 37) - with persisting inflammatory 
changes in the GM, subgroup 2 (n = 63) - with the 
absence of inflammatory changes, followed by a 
discriminant analysis to identify risk factors that 
contribute to the maintenance of the inflammatory 
process in the GM.
All children underwent the evaluation of their complaints, 
physical examination according to standard methods. 
In addition, routine laboratory methods were carried 
out: Immunological examination - determination of C3 
and C
4
 complement components, interleukin (IL-1β), 
IL-8, IL-4, and IL-10, IG of classes M, G, and A, 
using the ProCon reagent kit (LLC Protein Contour, 
St. Petersburg) by enzyme-linked immunosorbent 
assay, determination of the level of gastrointestinal 
neuropeptides (cholecystokinin [CCK] and secretin by 
ELISA using a reagent kit from Peninsula Laboratories, 
Inc. [USA]), and diagnosis of HP with the definition 
of facto pathogenicity of CagA. The method of gas 
chromatography–mass spectrometry determining the 
species-specific fatty acids of the structural components 
of bacterial cells was used to assess the state of the 
parietal microbiota of the small intestine.
Instrumental Research Methods Included
Esophagogastroduodenoscopy with histological 
examination of the biopsy specimens obtained, intragastric 
topographic pH-metry, ultrasound examination of the 
abdominal organs, and ultrasound examination of the 
motor function of the stomach. Since the cross-section 
of the antrum of the stomach in the sagittal plane has the 
shape of an ellipse, its area was calculated based on the 
formula of the Greek ellipse - LDхAP/4, where LD is 
the longitudinal diameter and AP is the anteroposterior 
diameter. Measurements were performed on an empty 
stomach, immediately after taking a standard breakfast 
and then every 20 min for 1 h.
Statistical analysis was performed using the statistical 
package SSPS 13.0 for Windows. The resulting data 
were analyzed using descriptive statistics with the 
calculation of arithmetic mean (M) and standard 
deviation. The normal distribution was estimated 
using the Shapiro–Wilk criterion. The evaluation 
of the statistical significance of differences for data 
with a normal distribution was carried out using 
Student’s t-test for dependent samples. To compare 
the frequency of occurrence of qualitative data in two 
groups, the criterion of compliance χ2 was used, the 
confidence interval for the odds ratio was calculated. 
The results were evaluated as statistically significant 
at a probability level of P < 0.05.
RESULTS
The study of the characteristics of the endoscopic 
picture showed that in the acute phase of CGD, 
common gastritis was unreliable more often 
diagnosed in 58.1% of children against 41.9% with 
antral gastritis (P > 0.05), signs of impaired motility 
such as gastroesophageal reflux were revealed 
in 12.2% and 26.4%, respectively. 3 months and 
6 months later, visual changes of the GM in the form 
of moderate hyperemia persisted in 21% and 24% of 
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children, P > 0.05 (signs of pangastritis were observed 
in 19% and 11% of children, respectively).
The morphological picture in the exacerbation phase was 
characterized by the presence of lymphoplasmacytic 
infiltration in the body of the stomach (74.8%), mostly 
slightly (43.%), and moderately (23.9%) expressed in 
the antrum of the stomach (100%). At the same time, 
morphological changes in the body of the stomach 
were more frequent than endoscopic manifestations 
(74.8% vs. 58.3%, P = 0.0037). Signs of vague atrophy 
were found in 23.2% of children (16.1% - in the 
antrum and fundus). 3 and 6 months later, the number 
of children with signs of inflammatory changes 
significantly decreased to 37%, while the number of 
patients with signs of unspecified atrophy decreased 
significantly only due to patients with changes in 
the antrum. The obtained results demonstrated that, 
despite the conducted eradication therapy and clinical 
improvement, the morphological changes in the GM in 
the form of moderate lymphoplasmacytic infiltration 
and atrophy persisted after 6 months in 37% and 9%, 
respectively [Table 1].
The pH metrics showed that in the acute phase in 
children, the normacid state prevailed (67.1%/104 
children), the hyperacid state was detected in 
30.3%/47 cases. 6 months after treatment, the hyperacid 
state persisted in 14% of children. At the same time, 
in the exacerbation phase, a predominantly acid-
neutralizing dysfunction of the stomach was noted, 
which positively correlated with the acceleration of 
emptying the antrum of the stomach (r1 = 0.38 and 
r1 = 0.44, respectively, P < 0.05). In the remission 
phase, normalization of the acid-producing function 
was noted with the maintained acid-neutralizing 
dysfunction.
Changes in the motor-evacuation function of the 
stomach were characterized in the exacerbation phase 
by disturbances in the accommodation processes in 
response to food intake and accelerated emptying of 
the stomach in 98% of children. A positive correlation 
between the acceleration of gastric motility and the 
severity of pain after eating (r = 0.68, P < 0.05) is shown. 3 
and 6 months after eradication therapy, an improvement 
in the accommodation of the stomach was noted (after 
6 months, it was approaching the indicators of healthy 
children) and the rate of gastric emptying (Δ area of 
the antrum) comparable to that of healthy children. 
However, no complete restoration of consistency in the 
motility of the stomach and the duodenum (dimensions 
of the antrum after 20 and 60 min) was noted [Table 2]. 
When assessing the dispersion of indicators of the size 
of the antrum in the acute phase and in remission, we 
found that in 25% of children with CGD, changes in 
gastric motility persisted after 3 and 6 months with Δ 
antral area of 57.7% ± 10.5 compared with the same 
indicator in healthy children - 34.4% ± 6.8 (P = 0.04).
The revealed motor disorders were accompanied by 
a decreased postprandial level of gastrointestinal 
hormones - secretin and CCK in children with 
acute CGD, compared with healthy children, which 
positively correlated with an increase in the secretion 
of hydrochloric acid, acceleration of the evacuation 
activity of the antrum of the stomach, and the 
detection of hypomotor dyskinesia of the gallbladder 
of the antrum (GB) (r = 0.43, r = 0.54 and r = 0.62, 
respectively, P < 0.05). In the remission phase, the 
indicators of these hormones increased but did not 
reach the level of healthy children [Table 3]. The 
resulting changes on the part of secretin and CCK, 
which are involved in regulating the functioning of 
the gastroduodeno-pancreatic hepatobiliary complex, 
Table 1: Characteristics of the morphological picture of the GM in children with CGD before treatment and 3 and 6 
months after therapy




















Mild 67 (43.2) 25 (25)* 20 (20)** 31 (31) 20 (20) 21 (21)
Moderate 37 (23.9) 11 (11)* 7 (7)** 69 (44.5) 13 (13)* 9 (9)**
Severe 12 (7.7) 0 0 39 (25.2) 10 (10)* 7 (7)**
Total 116 (74.8) 36 (36)* 27 (27)** 155 (100) 43 (43)* 37 (37)**
Аtrophy
Mild 19 (12.2) 10 (10) 7 (7) 22 (14.2) 9 (9) 5 (5)**
Moderate 6 (3.9) 1 (1) 2 (2) 14 (9) 2 (2)* 2 (2)**
Severe 0 0 0 0 0 0
Total 25 (16.1) 11 (11) 9 (9) 36 (23.2) 11 (11)* 7 (7)**
Small intestine metaplasia
Mild 0 0 0 17 (11) 3 (3)* 4 (4)**
Moderate 0 0 0 0 0 0
Severe 0 0 0 0 0 0
Total 0 0 0 17 (11) 3 (3)* 4 (4)**
*Differences between children with CGD in the exacerbation phase and 3 months after eradication therapy are significant, P<0.05. **Differences between 
children with CGD in the exacerbation phase and 6 months after eradication therapy are significant, P<0.05
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emphasize the complex nature of changes in the 
paracrine regulation, affecting not only motility and 
secretion of the stomach but also GB and pancreas.
Evaluation of the status of indicators of the innate 
and adaptive immunity in children with acute CGD 
revealed changes characteristic of the infectious 
process with an increase in the blood plasma level of 
the components of the complement system (2 times 
higher C3, 3 times higher C4), and increased IgM, 
IgG, and lower IgA. Changes in the level of cytokines 
were characterized by a 2-fold increase in the level 
of IL-1β, a moderate increase in IL-10 values, tumor 
necrosis factor α, and a decrease in IL-8 [Table 4].
After 3 and 6 months of eradication, a tendency toward 
normalization of altered indices of innate and adaptive 
immunity was revealed. Despite the positive dynamics, 
in 19% of children, an elevated content of C3 and C4 
components of the complement remained, positively 
correlated with the presence of the pathogenicity 
factor CagA HP (r = 0.64, P < 0.01) and an increase in 
the number of conditionally pathogenic flora (CPF), 
especially Bacteroides (r = 0.58 and r = 0.49, P < 0.01).
The study of microbial metabolites of the parietal 
microflora in children with CGD allowed us to 
document the reduction in the number of representatives 
of the symbiotic microbiota - bifidobacteria, 
lactobacilli, propionibacteria, eubacteria (Eubacterium 
moniliforme, Eubacterium nodatum, and Eubacterium 
sabureum), Faecalibacterium prausnitzii in excessive 
concentrations of representatives of CPF - clostridia 
(Clostridium hystolyticum, Clostridium propionicum, 
Table 2: Dynamics of changes in motor‑evacuation indicators in children with CGD 3 and 6 months after eradication 
therapy
US findings (М±SD) Children with CGD, 
exacerbation, n=60
3 months after 
treatment, n=60




Antrum size on an empty stomach (cm2) 8.6±2.1 8.9±1.8 9.0±1.7 9.5±1.8
Antrum size immediately after eating (cm2) 10.0±1.3# 9.7±1.4* 10.3±1.7 10.8±2.05
Antrum size 20 min after eating (cm2) (М±SD) 8.5±1.45# 9.11±1.3*/** 8.1±0.9**/*** 9.8±1.8
Antrum size 40 min after eating (cm2) (М±SD) 9.4±0.98# 9.67±1.3**/*** 8.01±0.8*/*** 8.4±1.2
Antrum size 60 min after eating (cm2) (М±SD) 8.9±1.2# 9.3±1.4**/*** 8.0±0.9*/**/*** 7.0±1.4
Dynamics of changes in the antrum area 
(gastric emptying rate), %
48.03±6.4# 41.4±5.3 42.5±6.4 34.4±7.1
#Differences between children with acute CGD and the control group are significant, P<0.05. *Differences between children with acute CGD and 3 months 
after treatment are significant, P<0.05. **Differences between children with CGD 3 and 6 months after treatment and the control group are significant, P<0.05. 
***Differences between children with CGD 3 and 6 months after treatment are significant, P<0.05
Table 4: The content of components of the complement system, cytokines, and immunoglobulins (IG) in the blood 
plasma of children with CGD during exacerbation and remission
Indicators Exacerbation p‑d of 
CGD, n=155, (М±SD)
3 months after treatment, 
n=100, (М±SD)





# 2.8±0.7* 2.07±0.8**/*** 1.46±0.5
С
4
 (g/l) 0.84±0.13# 0.72±0.1 0.68±0.08** 0.25±0.1
IgM (g/l) 2.37±0.5# 1.86±0.7* 1.38±0.5**/*** 1.14±0.6
IgG (g/l) 16.87±3.8# 16.62±5.3 15.1±4.6**/*** 14.4±2.3
IgA (g/l) 1.36±0.2# 1.58±0.5* 1.74±0.6**/*** 2.39±0.4
IgE (U/ml) 67.8±13.6# 67.06±10.3 61.3±9.7**/*** 57.2±10.8
IL-1β (pg/ml) 5.20±1.2# 4.82±1.1* 4.40±1.3** 3.22±0.6
IL-8 (pg/ml) 26.23±6.5# 29.7±7.4* 36.5±6.6**/*** 46.5±8.4
IL-10 (pg/ml) 8.42±1.8 8.35±2.1 8.34±1.5 8.24±2.3
TNF-α (pg/ml) 3.51±0.7# 3.45±0.6 2.99±0.8** 2.66±0.4
CIC (U/ml) 18.7±4.1# 17.68±3.8* 14.5±2.6**/*** 9.77±2.4
#Differences between children with acute CGD and the control group are significant, P<0.001. *Differences between children with CGD in the exacerbation phase 
and 3 months after eradication therapy are significant, P<0.05. **Differences between children with CGD in the exacerbation phase and 6 months after eradication 
therapy are significant, P<0.05. ***Differences between children with CGD 3 and 6 months after the successful eradication therapy are significant, P<0.05
Table 3: The content of secretin and CCK in children with CGD in different phases of the disease
Data Secretin, ng/ml (М±SD) Cholecystokinin (CCK), ng/ml (М±SD)
Basal level Postprandial level Basal level Postprandial level
CGD exacerbation p-d (n=30) 0.81±0.04 0.86±0.02# 0.51±0.03 0.6±0,04#
3 months after treatment (n=30) 0.8±0.02 0.9±0.04* 0.52±0.02 0.67±0.03*
3 months after treatment (n=30) 0.78±0.02**/*** 0.87±0.03**/*** 0.55±0.03**/*** 0.63±0.02**/***
Healthy children (n=30) 0.79±0.03 0.91±0.04 0.54±0.02 0.68±0.03
#Differences between children with acute CGD and the control group are significant, P<0.05. *Differences between children with CGD in the exacerbation 
phase and 3 months after eradication therapy are significant, P<0.05. **Differences between children with CGD in the exacerbation phase and 6 months after 
eradication therapy are significant, P<0.05. ***Differences between children with CGD 3 and 6 months after the eradication therapy are significant, P<0.05
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and Clostridium ramosum), actinomycetes, streptococci, 
and Bacteroides fragilis.
We evaluated the risk factors for the preservation of 
GM morphofunctional changes in children with CGD 
after 6 months. To this end, all the children studied were 
divided into two subgroups depending on the presence 
(subgroup 1, n = 37) or absence (subgroup 2, n = 63) of 
inflammatory changes in GM - the canonical correlation 
coefficient is 0.34, χ2 = 55.34, P < 0.01. Based on our 
discriminant analysis, we identified the following 
risk factors: The presence of the pathogenicity factor 
HP (CagA+), changes in the intestinal microbiota 
(deficiency of obligate microorganisms, excessive 
proliferation of CPF), impaired motor function of the 
stomach and duodenum (presence of antroduodenal 
dysregulation), immune changes (increased levels of 
C3 and C4 components of the compliment), impaired 
vegetative regulation (reduced vegetative resistance), 
and the presence of comorbid pathology (more than 
three concomitant diseases).
DISCUSSION
Thus, it was shown that after 3 and 6 months of 
successful eradication of HP infection and clinical 
improvement in CGD, the following changes remained 
in children: Morphological changes in GM were 
detected in the form of moderate lymphoplasmacytic 
infiltration and atrophy in 37% and 9%, respectively, 
incomplete normalization of the secretory function 
of the stomach - hyperacid state preserved in 14% 
of children after 6 months, signs of impaired gastric 
motility remained in 25% of children (decrease in 
accommodation, accelerated motility) comparable 
with the data of the acute phase, and changes in 
the level of gastrointestinal hormones (decrease 
in stimulated secretin and CCK) involved in the 
regulation of the functioning of the gastroduodeno-
pancreatic hepatobiliary complex with impaired 
motility and secretion of the stomach, gallbladder, and 
pancreas, persisted; there were changes in the immune 
system - a reduced level of IgA with increasing levels 
of C3 and C4; on the part of the parietal microflora, a 
decrease in the number of symbiotic representatives 
of normal flora (bifidobacteria, lactobacteria, 
propionobacteria, and eubacteria) with excessive 
proliferation of conditionally pathogenic microflora 
(clostridia, streptococci, and Bacteroides) has been 
revealed.
Summary
During remission of CGD in 37% of cases, 
lymphoplasmacytic infiltration of GM and uncertain 
atrophy persisted in 9% of children. The risk factors 
that support GM pathological changes include the 
presence of the pathogenicity factor HP (CagA+), 
changes in the intestinal microbiota (deficiency of 
obligate microorganisms, excessive proliferation of 
CPF), impaired motor function of the stomach and 
duodenum (presence of antroduodenal dysregulation), 
immune changes (increased levels of C3 and C4 
components of the compliment), impaired vegetative 
regulation (reduced vegetative resistance), and the 
presence of comorbid pathology (more than three 
concomitant diseases). The obtained data dictate 
the need to isolate a group of patients with CGD 
with risk factors for the maintaining inflammatory 
changes and manifestations of unspecified atrophy to 
further explore the possibilities of the individualized 
prevention programs.
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